Square Is Leaving Hemp. The Bigger Question Is Why Banks and Processors Keep Leaving.
Square Is Leaving Hemp. The Bigger Question Is Why Banks and Processors Keep Leaving. The Hemp Industry Has Spent a Decade Outsourcing C...
Speculation about government health insurance covering CBD treatments created brief excitement across the hemp industry last week, but the reality emerging from proposed Medicare policy changes tells a far more limited story. The Centers for Medicare & Medicaid Services proposal published in the Federal Register in early December 2025 would cover only a narrow list of hemp-derived products, none of which include cannabidiol (CBD).
The proposed policy change would allow Medicare coverage for hulled hemp seed, hemp seed protein powder, and hemp seed oil under certain plans. These basic food ingredients contain no cannabinoids and represent a fraction of the $28.3 billion U.S. hemp sector's product portfolio.
Bloomberg reported in late November that the Centers for Medicare & Medicaid Services was considering covering CBD treatments for certain seniors, triggering widespread industry optimism. The speculation gained momentum after Howard Kessler, a billionaire financier and CBD advocate who belongs to President Donald Trump's Mar-a-Lago club, met with Health and Human Services Secretary Robert F. Kennedy Jr.
Kessler's Commonwealth Project produced a video suggesting CBD as a potential treatment for seniors, which Trump reposted on Truth Social. The visibility of this advocacy effort led many in the hemp industry to anticipate significant policy shifts that could provide government-subsidized access to CBD products for Medicare beneficiaries.
However, the actual proposal that appeared in the Federal Register on December 1, 2025, delivers considerably less than anticipated. The policy would "state more precisely that cannabis products that are illegal under applicable State or Federal law," including U.S. Food and Drug Administration regulations, "are not allowable" for Medicare coverage.
The FDA's regulatory stance on CBD presents a fundamental obstacle to Medicare coverage. The agency has repeatedly stated that existing regulations for food and supplements aren't appropriate for CBD, which is not an approved food additive. This position effectively excludes most CBD products from potential Medicare reimbursement, regardless of their legal status under state law or the 2018 Farm Bill.
Currently, only one FDA-approved CBD-based pharmaceutical drug exists: Epidiolex, available exclusively via prescription for treating certain seizure disorders. This pharmaceutical product already has pathways to coverage under existing Medicare prescription drug benefits, making the proposed policy change largely irrelevant for patients who might benefit from CBD treatments.
The proposed Medicare policy represents a refinement of earlier guidance unveiled in April 2025 that specifically excluded cannabis products from coverage under certain Medicare plans "as they are illegal substances under federal law." The new language attempts to clarify which hemp-derived products might qualify for coverage while maintaining the exclusion for cannabinoid-containing items.
The limited scope of potential Medicare coverage arrives as the hemp sector confronts what many characterize as an extinction event. President Trump signed legislation in November 2025 that closes the loophole in the 2018 Farm Bill, redefining hemp to exclude hemp-derived THC products. This ban, scheduled to take effect in November 2026, also outlaws CBD products containing 0.4 milligrams of THC or more per container.
Hemp advocates warn that this prohibition effectively criminalizes most of the estimated $28.3 billion annual U.S. hemp sector. The combination of restricted Medicare coverage and the looming ban on hemp-derived THC creates a challenging regulatory environment for businesses that have built operations around CBD and other cannabinoid products.
The three hemp products potentially eligible for Medicare coverage—hulled hemp seed, hemp seed protein powder, and hemp seed oil—represent basic nutritional ingredients rather than the cannabinoid-rich extracts that constitute the majority of hemp industry revenue. These food ingredients have been widely available through conventional retail channels for years without requiring specialized hemp industry infrastructure.
The proposed Medicare policy changes do nothing to advance the possibility of health insurance coverage for medical cannabis products. As long as cannabis remains a federally controlled substance, government-subsidized health insurance programs cannot reimburse for marijuana products regardless of state medical cannabis laws.
The distinction between hemp-derived products and cannabis products continues to create regulatory complexity. While the 2018 Farm Bill legalized hemp defined as cannabis plants containing no more than 0.3% THC, the FDA maintains authority over how hemp-derived ingredients can be used in foods, supplements, and other consumer products.
This regulatory framework leaves the hemp industry in a precarious position. Products that comply with the Farm Bill's THC threshold may still violate FDA regulations governing food additives and dietary supplements. The proposed Medicare coverage for basic hemp food ingredients doesn't resolve these underlying regulatory tensions.
As hemp businesses navigate this restrictive regulatory environment, maintaining product quality and accurate labeling becomes increasingly critical. Companies operating in sectors facing potential prohibition need comprehensive documentation systems that track ingredient sources, verify compliance with evolving regulations, and demonstrate product integrity to regulators, payment processors, and other stakeholders.
The limited Medicare coverage proposal underscores how quickly policy expectations can shift in highly regulated industries. Businesses that invest in robust compliance infrastructure position themselves to adapt as regulations change, whether those changes expand or restrict market access.
Operating in the complex hemp and supplement regulatory environment? Contact Qredible to learn how Q-Trust can help you maintain comprehensive quality management and compliance documentation as regulations continue to evolve.
Source: MJBizDaily Staff. "Medicare proposes covering certain hemp products." MJBizDaily, December 1, 2025.
